Safety and Efficacy of the Combination of Selinexor, Lenalidomide and Dexamethasone (SRd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

被引：1

作者：

White, Darrell ^{[1
]}

LeBlanc, Richard ^{[2
]}

Venner, Chritopher ^{[3
]}

Bahlis, Nizar J. ^{[4
]}

Lentzsch, Suzanne ^{[5
]}

Gasparetto, Cristina J. ^{[6
]}

Chen, Christine ^{[7
]}

Lipe, Brea ^{[8
]}

Sutherland, Heather ^{[9
]}

Tuchman, Sascha ^{[10
]}

Baljevic, Muhamed ^{[11
]}

Kotb, Rami ^{[12
]}

Sebag, Michael ^{[13
]}

Callander, Nancy ^{[14
]}

Bensinger, William ^{[15
]}

Kai, Kazuharu ^{[16
]}

Liu, Jianjun ^{[16
]}

Sheehan, Heidi ^{[16
]}

Estepan, Daniel Nova ^{[16
]}

Shah, Jatin ^{[16
]}

Schiller, Gary J. ^{[17
]}

机构：

[1] Dalhousie Univ, Halifax, NS, Canada

[2] Univ Montreal, Hop Maisonneuve Rosemont, Montreal, PQ, Canada

[3] Cross Canc Inst, Edmonton, AB, Canada

[4] Univ Calgary, Calgary, AB, Canada

[5] Columbia Univ, Med Ctr, New York, NY USA

[6] Duke Univ, Hematol Malignancies & Cellular Therapy, Durham, NC USA

[7] Princess Margaret Hosp, Toronto, ON, Canada

[8] Univ Rochester, Coll Med, New York, NY USA

[9] Univ British Columbia, Vancouver, BC, Canada

[10] Univ N Carolina, Chapel Hill, NC 27515 USA

[11] Univ Nebraska Med Ctr, Omaha, NE USA

[12] Canc Care Manitoba, Winnipeg, MB, Canada

[13] McGill Univ, Hlth Ctr, Montreal, PQ, Canada

[14] Univ Wisconsin, Carbone Canc Ctr, Madison, WI 53706 USA

[15] Swedish Canc Inst, Myeloma & Transplant Program, Seatlle, WA USA

[16] Karyopharm Therapeut Inc, Newton, MA USA

[17] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2019年 / 19卷 / 10期

关键词：

Lenalidomide; novel agents; relapsed/refractory multiple myeloma;

D O I：

10.1016/j.clml.2019.09.084

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

OAB-083

引用

页码：E55 / E55

页数：1

共 50 条

[1] Selinexor, Lenalidomide and Dexamethasone (SRd) for Patients with Relapsed/Refractory and Newly Diagnosed Multiple Myeloma
White, Darrell J.
LeBlanc, Richard
Baljevic, Muhamed
Bahlis, Nizar J.
Lentzsch, Suzanne
Venner, Christopher P.
Gasparetto, Cristina
Chen, Christine I.
Lipe, Brea
Tuchman, Sascha A.
Sutherland, Heather J.
Kotb, Rami
Sebag, Michael
Callander, Natalie S.
Bensinger, William I.
Rossi, Adriana C.
Sheehan, Heidi
Van Domelen, Dane
Zhou, Tianjun
Kazuharu, Kai
Shah, Jatin
Shacham, Sharon
Kauffman, Michael G.
Schiller, Gary J.
BLOOD, 2020, 136
[2] Safety and Efficacy of the Combination of Selinexor, Lenalidomide and Dexamethasone (SRd) in Patients with Newly Diagnosed Multiple Myeloma
White, Darrell J.
Lentzsch, Suzanne
Gasparetto, Cristina
Bahlis, Nizar
Chen, Christine I.
Lipe, Brea C.
Schiller, Gary J.
Tuchman, Sascha A.
Sutherland, Heather J.
Kotb, Rami
Leblanc, Richard
Sebag, Michael
Venner, Christopher P.
Callander, Natalie Scott
Bensinger, William I.
Sheehan, Heidi
Chai, Yi
Kai, Kazuharu
Shah, Jatin
Shacham, Sharon
Kauffman, Michael G.
Baljevic, Muhamed
BLOOD, 2019, 134
[3] Selinexor in Combination with Pomalidomide and Dexamethasone (SPd) for Treatment of Patients with Relapsed Refractory Multiple Myeloma (RRMM)
Chen, Christine I.
Bahlis, Nizar J.
Gasparetto, Cristina
Tuchman, Sascha A.
Lipe, Brea
Baljevic, Muhamed
Kotb, Rami
Sutherland, Heather J.
Bensinger, William I.
Sebag, Michael
LeBlanc, Richard
Venner, Christopher P.
Schiller, Gary J.
Lentzsch, Suzanne
Callander, Natalie S.
Rossi, Adriana C.
Sheehan, Heidi
Van Domelen, Dane
Kazuharu, Kai
Wang, Hongwei
Shah, Jatin
Shacham, Sharon
Kauffman, Michael G.
White, Darrell J.
BLOOD, 2020, 136
[4] Daratumumab, lenalidomide, and dexamethasone (DRd) vs lenalidomide and dexamethasone (Rd) in relapsed or refractory multiple myeloma (RRMM): Efficacy and safety update (POLLUX).
Bahlis, Nizar J.
Moreau, Philippe
Nahi, Hareth
Plesner, Torben
Goldschmidt, Hartmut
Suzuki, Kenshi
Orlowski, Robert Z.
Rabin, Neil
Leiba, Merav
Oriol, Albert
Chari, Ajai
Miguel, Jesus San
Richardson, Paul G.
Usmani, Saad Zafar
O'Rourke, Lisa Marie
Wu, Kaida
Casneuf, Tineke
Chiu, Christopher
Qin, Xiang
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[5] Safety and Efficacy of Daratumumab with Lenalidomide and Dexamethasone in Relapsed or Relapsed, Refractory Multiple Myeloma
Plesner, Torben
Arkenau, Hendrik-Tobias
Lokhorst, Henk M.
Gimsing, Peter
Krejcik, Jakub
Lemech, Charlotte
Minnema, Monique C.
Lassen, Ulrik
Laubach, Jacob P.
Ahmadi, Tahamtan
Yeh, Howard
Guckert, Mary E.
Feng, Huaibao
Brun, Nikolai Constantin
Lisby, Steen
Basse, Linda
Palumbo, Antonio
Richardson, Paul G.
BLOOD, 2014, 124 (21)
[6] A US BUDGET IMPACT MODEL FOR SELINEXOR IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM)
Bassali, J.
Gould, I
Mladsi, D. D.
Kaye, J. A.
Shah, J.
Mehta, J.
VALUE IN HEALTH, 2020, 23 : S33 - S33
[7] SAFETY AND EFFICACY OF DARATUMUMAB WITH LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED OR RELAPSED, REFRACTORY MULTIPLE MYELOMA
Plesner, T.
Arkenau, H. T.
Lokhorst, H. M.
Gimsing, P.
Krejcik, J.
Lemech, C.
Minnema, M. C.
Lassen, U.
Ahmadi, T.
Yeh, H.
Guckert, M.
Brun, N. C.
Lisby, S.
Basse, L.
Palumbo, A.
Richardson, P. G.
HAEMATOLOGICA, 2014, 99 : 104 - 104
[8] A US Budget Impact Model for Selinexor in Combination with Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
Gould, Ian
Bassali, Jan
Mehta, Jyotsna
Shah, Jatin
Mladsi, Dee Dee
BLOOD, 2019, 134
[9] Selinexor for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
Anum, Babar
Hina, Zubair
Mainoma, Bano
Sana, Rafique
Arzu, Shahid
Maham, Babar
Waleed, Madeeha S.
Arslan, Inayat
Danish, Safi
AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 : S29 - S29
[10] A REAL-WORLD EFFICACY AND SAFETY ANALYSIS OF CARFILZOMIB-LENALIDOMIDE-DEXAMETHASONE (KRD) COMBINATION IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
Caratozzolo, I.
Tacchetti, P.
Zambello, R.
Pantani, L.
Antonioli, E.
Mancuso, K.
Buda, G.
Rocchi, S.
Canepa, L.
Rizzello, I.
Gamberi, B.
Barila, G.
Testoni, N.
Marzocchi, G.
Zamagni, E.
Cavo, M.
HAEMATOLOGICA, 2019, 104 : 66 - 66

← 1 2 3 4 5 →